One study reported that a humoral immune response to NY‐ESO‐1/LAGE‐1 can be detected in 1/3 of patients with ovarian cancer expressing NY‐ESO‐1/LAGE‐1.51 This evidence concerns the gene CTAG2 and ovarian carcinoma.